DGAP-News

CureVac Announces Voting Results of General Meeting

Issuer: CureVac / Key word(s): AGM/EGM CureVac Announces Voting Results of General Meeting 22.06.2022 / 22:05 The issuer is solely responsible for the content of this announcement.

CureVac Announces Voting Results of General Meeting

 

TÜBINGEN, Germany / BOSTON, USA – June 22, 2022 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general meeting.

 

The shareholders of the Company voted in favor of all proposals. The proposals voted in favor for included the re-appointment of Craig Tooman, appointment of Dr. Debra Barker and appointment of
Dr. Klaus Schollmeier as supervisory board members, the re-appointment of Dr. Franz-Werner Haas and appointment of Dr. Malte Greune as managing directors.

 

A table containing tabulations of the votes casted is expected to be released in the coming days.

 

About CureVac

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 900 people at its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.